Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid 2Leukemia 2Primary Myelofibrosis 1Multiple Myeloma 1Leukemia, Monocytic, Acute 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Glioma 1Clonal Cytopenia of Undetermined Significance 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Cytarabine 9fludarabine 5Imatinib Mesylate 5thymoglobulin 3fludarabine phosphate 3Tacrolimus 3Sirolimus 3Methotrexate 3Cyclophosphamide 3Busulfan 3Azacitidine 3zosuquidar trihydrochloride 2venetoclax 2ponatinib 2nilotinib 2enasidenib 2bosutinib 2RO6839921 2Mycophenolic Acid 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Behavior Therapy 2Antilymphocyte Serum 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1quizartinib 1plerixafor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid × enasidenib × Clear all
NCT05282459 2026-04-17

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Stanford University

Phase 1/2 Completed
17 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid

NCT02577406 2025-05-18

IDHENTIFY

Celgene

Phase 3 Completed
319 enrolled 29 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡